Comparison of myo-inositol and metformin on glycemic control, lipid profiles and gene expression related to insulin and lipid metabolism in PCOS women: arandomized controlled clinical trial
Publish place: 3rd debatable topics on obstetrics gynecology & infertility
Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 394
نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
DTOGIMED03_061
تاریخ نمایه سازی: 26 بهمن 1398
Abstract:
Background and Aim : This investigation was conducted to evaluate comparison of myo-inositol andmetformin on glycemic control, lipid profiles and gene expression related to insulin and lipid metabolismin women with polycystic ovary syndrome (PCOS).Methods : This randomized controlled trial was conducted on 53 women with PCOS, aged 18-40 yearsold. Subjects were randomly allocated into two groups to take either myo-inositol (n=26) or metformin(n=27) for 12 weeks. Glycemic control and lipid profiles were determined at baseline and after the 12-weekintervention. Gene expression related to insulin and lipid metabolism was done on peripheral bloodmononuclear cells (PBMCs) of PCOS women using RT-PCR method.Results : Myo-inositol supplementation, compared with metformin, significantly reduced fasting plasmaglucose ( -5.12 mg/dL; 95% CI, -8.09, -2.16; P=0.001), serum insulin levels ( -1.49 μIU/mL; 95% CI, -2.28, -0.70; P<0.001), homeostasis model of assessment-insulin resistance ( -0.36; 95% CI, -0.55, -0.17;P<0.001), serum triglycerides ( 12.42 mg/dL; 95% CI, -20.47, -4.37; P=0.003) and VLDL-cholesterollevels ( -2.48 mg/dL; 95% CI, -4.09, -0.87; P=0.003), and significantly increased the quantitative insulinsensitivity check index ( 0.006; 95% CI, 0.002, 0.01; P=0.006) compared with metformin. Moreover, myoinositolsupplementation upregulated gene expression of peroxisome proliferator-activated receptor gamma(PPAR- ) (P=0.002) compared with metformin.Conclusion : Overall, taking myo-inositol, compared with metformin, for 12 weeks by women with PCOShad beneficial effects on glycemic control, triglycerides and VLDL-cholesterol levels, and gene expressionof PPAR-γ.
Keywords:
Authors
Fatemeh Foroozanfard
Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan,I.R. Iran
Zatollah Asemi
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences,Kashan, I.R. Iran
Esmat Aghadavod
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences,Kashan, I.R. Iran